drugset / Trial / NCT02546297

Comparisons of Inhaled LAMA or LAMA+LABA or ICS+LABA for COPD With Bronchiectasis

NCT02546297

Phase 4 Unknown 90 enrolled Shanghai Pulmonary Hospital, Shanghai, China
RandomizedCrossoverQuadruple-blindTreatment

Summary

The purpose of this study is to determine which treatment is more effective and safer for the patients in COPD C group with bronchiectasis.The research results will help guide physicians to select appropriate individualized treatment and hopefully provide some evidence-based medicine proofs for revising guide.

Timeline

Start
2017-09-15
Primary completion
2020-09-15
Completion
2021-03-01

Drugs

EvaluationDrugModalityDoseRoute
Comparator Symbicort Unknown Inhaled
Comparator Tiotropium Other / unclassified Inhaled

Indications